PEB to Participate in Upcoming Investor Conferences

14 September 2026
PACIFIC EDGE TO PARTICIPATE IN UPCOMING INVESTOR
CONFERENCES


DUNEDIN, New Zealand – Pacific Edge (NZX/ASX: PEB) announces that it will participate in
several upcoming investor conferences across Australia and New Zealand in the coming weeks.
• New Zealand Shareholders Association’s The Horizon for Healthcare, Auckland,
September 16
• Evans and Partners Small Cap Healthcare Conference, Sydney, September 16
• ASX SMIDcaps, Sydney, September 23
• NZX Tech Investor Day, Auckland, October 8
• Bell Potter Healthcare, Virtual, November 17
Pacific Edge has revised its corporate presentation for those activities and is making new slides
available on the NZX and ASX. The presentation is also available on Pacific Edge’s investor
website (HERE)



ENDS
For more information:
Investors: Media:
Dr Peter Meintjes Richard Inder
Chief Executive The Project
Pacific Edge P: +64 21 645 643
P: +64 22 032 1263

OVERVIEW
Pacific Edge: www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way
in the development and commercialization of bladder cancer diagnostic and prognostic tests
for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in
Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its
wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

2

Cxbladder: www.cxbladder.com
Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of
urothelial cancer in patients presenting with hematuria and those being monitored for recurrent
disease. The tests help improve the overall patient experience, while prioritizing time and
clinical resources to optimize practice workflow and improve efficiency.
Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than
twenty-five peer reviewed publications, and Cxbladder Triage is now included in the American
Urological Association’s Microhematuria Guideline. To drive increased adoption and improved
patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies
designed to generate further clinical utility evidence.
Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and
South America. In the US, the test has been used by over 5,000 urologists who have ordered
more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the
population via public healthcare and all residents have the option of buying the test online.

---

INVESTOR CONFERENCE
Dr Peter Meintjes
Chief Executive Officer
1

GRANT GIBSON
Chief Financial Officer
DR PETER MEINTJES
Chief Executive Officer
PRESENTING TODAY
2

This presentation has been prepared by Pacific Edge Limited (PEL) solely
to provide interested parties with further information about PEL and its
activities at the date of this presentation).
A reference in this Important Notice and Disclaimer to the Information
means the information in this presentation and any verbal remarks made
by PEL directors or management(including answers to questions) in
respect of the matters addressed in this presentation.
Unless otherwise specified, the Information is stated at the date of this
presentation.The Information should be read in conjunction with PEL’s
Annual Report, half-year financial statements, and continuous disclosure
announcements released to NZX and ASX at
•www.nzx.com/companies/PEB; and
•https://www.asx.com.au/markets/company/PEB
Information of a general nature
The Information is of a general nature only and does not purport to be
complete or comprehensive. It does not contain all the information that
a person may require in evaluating or making an investment decision in
respect of PEL shares. Nor does it take into account any person’s
objectives or circumstances.
Not an offer
The Information is for informational purposes only. It is not an invitation
or offer of securities for subscription, purchase or sale for any purpose
or in any jurisdiction.
Not financial product advice
The Information does not constitute legal, financial, tax, investment, or
financial product advice, and is not a recommendation to invest in or
deal with PEL shares.
Past performance, including past PEL share price performance, cannot be
relied on as an indicator of future performance, including in respect of
PEL’s future financial performance, PEL’s future financial position, or
future PEL share price performance. Any investment in PEL shares is
subject to various risks, including those set out on pages 26 to 28 of
PEL’s Capital Raising Presentation that was released by NZX and ASX on
11 May 2026. If you are considering investing in or dealing with PEL
shares, you are encouraged to read those risks carefully, and to seek
your own professional advice, before you do so.
Forward-looking statements
The Information contains forward-looking statements that relate to
future events, outcomes or circumstances. Forward-looking statements,
by their very nature, are based on assumptions, estimates or
expectations about the future and involve inherent risks and
uncertainties. Many of those assumptions, estimates, expectations, risks
and uncertainties are matters that are beyond PEL’s control. There is no
assurance that any forward-looking statement will be realized or
achieved. Actual results or circumstances could differ (potentially
materially) from those statements.
Non-GAAP financial information
The Information contains certain financial measures that are “non-GAAP
financial information” under the New Zealand Financial Markets
Authority Guidance Note on disclosing non-GAAP financial information
and “non-IFRS financial information” under the ASIC Regulatory Guide on
disclosing non-IFRS financial information (and potentially under other
regulatory guidelines or rules).
Such financial information and financial measures do not have
standardized meanings prescribed under NZ IFRS or IFRS and therefore,
may not be comparable to similarly titled measures presented by other
entities, and should not be construed as an alternative to other financial
measures determined in accordance with NZ IFRS, or IFRS).
Currency
All dollar values to in the Information are in New Zealand dollars unless
otherwise stated.
Effect of rounding
A number of figures, amounts, percentages, estimates, calculations of
value and fractions in the Information are subject to the effect of
rounding. Accordingly, the actual calculations may differ.
Disclaimer
PEL has sought to use reasonable care to prepare the Information.
However, PEL and its related bodies corporate and affiliates, and their
respective directors, officers, partners, employees, agents, associates
and advisers (each such person, a PEL Person) do not make or provide
any representation, warranty or assurance, express or implied, of any
nature in respect of the Information (including, without limitation, as to
the accuracy, reliability or completeness of any of the Information or as
to whether any forward-looking statement will be realized or achieved or
the likelihood of this occurring).
No PEL Person is required or under any obligation to update this
presentation and, except where required by law or applicable Listing
Rules, no PEL Person is required or under any obligation to update the
Information.
To the maximum extent permitted by law, each PEL Person disclaims,
and no PEL Person shall have any, liability of any nature (including,
without limitation, arising from any fault or negligence) arising from or
in connection with (1) any person’s reliance on or use of the Information;
(2) any errors in or omissions from the Information; or (3) any failure to
update or correct the Information.
IMPORTANT NOTICE AND DISCLAIMER
3

Pacific Edge is a world-leading cancer diagnostics company that develops and commercializes a suite
of urine-based, non-invasive tests for bladder cancer
The primary symptom of bladder cancer is hematuria (blood in the urine) which impacts ~7m
patients per each year in the US driving a global market opportunity of US$10.6 billion
1
Our proprietary Cxbladder tests are patented, non-invasive urine tests that have demonstrated
analytical, clinical, and economic value to clinicians, hospitals, payers and patients.
Cxbladder tests are supported by a robust portfolio of clinical evidence, and the AUA
2
has recognized
Cxbladder Triage with a ‘Grade A’ evidence rating – the only urine biomarker to achieve that rating
Novitas, our Medicare contractor, issued positive coverage for Cxbladder Triage and Triage Plus in
May 2026.We expect a final LCD
3
from Novitas by Jan 2027
4
Novitas issued favorable pricing of US$1,328/test for Triage Plus.Pacific Edge is targeting long-term
gross margins consistent with leading molecular diagnostic companies
5
PACIFIC EDGE – THE FIRST MOVER AND LEADER IN BLADDER CANCER DIAGNOSTICS
4
1.See slides 36-38 for assumptions
2.AUA = American Urological Association,
3.LCD = Local Coverage Determination.
4.Novitas must publish the final LCD or retire the draft LCD within 365 days after publishing a draft LCD
5.Requires testing volumes to scale and reimbursement coverage to broaden - Actual margins may differ

INTRODUCTION TO PACIFIC EDGE
5

BLADDER CANCER – A SIGNIFICANT GLOBAL HEALTHCARE CHALLENGE
THE STANDARD OF CARE – CYSTOSCOPY – IS HIGHLY INVASIVE, UNCOMFORTABLE AND COSTLY
6
1.Sievert et al (2009) Economic aspects of bladder cancer: what are the benefits and costs? World J Urol. 2009 Mar 7;27(3):295–300. doi: 10.1007/s00345-009-0395-z
2.World Cancer Research Fund. Statistics are from 2022. Growth due to aging population.
3.Average recurrence for low grade non-muscle invasive bladder cancer as published in Palou J et al (2012): Eur Urol 2012; 62: 118.
4.Company estimate
5.Source: Nursing Skills
1
st

Costliest cancer to
treat on a per-
patient basis
1
6
th
Most common
cancer in men
2
9
th
Most common
cancer world-wide
2
~614K
Cases per year
and growing
2
>220K
Deaths
per year
2
>50%
Recurrence
3
4.9m
Annual cystoscopies avoided globally if Cxbladder tests were used to
evaluate intermediate risk patients presenting with hematuria
4

CYSTOSCOPY

Cystoscopy is a procedure for men and women that inserts a camera on the end of a scope up the
urethra for a visual inspection of the lining of the bladder wall for signs of bladder cancer and other
diseases
5

CXBLADDER: TESTS TO RULE OUT CANCER OR PRIORITIZE PATIENTS
THE PATIENT CARE PATHWAY: HEMATURIA EVALUATION AND CANCER RECURRENCE SURVEILLANCE
1.RDM: Residual Disease Monitoring
2.TRM: Therapeutic Response Monitoring
3.NMIBC: non-muscle invasive bladder cancer
4.AV, CV, CU are Analytical Validity, Clinical Validity, and Clinical Utility which are required for medical policy and guidelines
5.AUA: American Urological Association
>130,000
Patients that have used
Cxbladder
>5,000
Urologists that have ordered
Cxbladder
>30
Publications demonstrating AV,
CV or CU evidence
4

Grade A
Evidence rating by the AUA
5
in its
2025 Microhematuria Guideline

THE CXBLADDER SUITE: TRIAGE AND TRIAGE PLUS FOR HEMATURIA EVALUATION
TESTS TO RULE OUT BLADDER CANCER AND IDENTIFY THOSE MOST NEEDING SPECIALIST CARE
HEMATURIA EVALUATION
NEGATIVE RESULT
RULE OUT BLADDER CANCER
The test combines a High Negative Predictive Value with
High Sensitivity (it picks up most cancers)


POSITIVE RESULT
PRIORITIZE SPECIALIST CARE
The test combines a High Positive Predictive Value with
High Specificity (it delivers few false positives)

PERFORMANCEKavalieris et al. (2015)
1
•Sensitivity: 95%
•Specificity: 45%
•Negative Predictive Value: 99%
•Positive Predictive Value: N/A
Harvey et al. (2025)
2
•Sensitivity: 93.6%
*
•Specificity: 98.2%
**
•Negative Predictive Value: 99.4%
*
•Positive Predictive Value: 74.6%
**
WHEN IT IS USED: Prior to cystoscopy
Prior to cystoscopy / as an adjunct /
3 weeks post cystoscopy
COMMERCIALLY AVAILABLEGlobally availableGlobally available
AUA GUIDELINEGrade A EvidenceAssessment expected in 2027
MEDICAREUS$760 (draft coverage)US$1,328 (draft coverage)
8
1.Kavalieris et al. (2015) A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma. BMC Urol 2015;15:23.
2.Harvey et al. (2025) Analytical Validation of the Cxbladder® Triage Plus Assay for Risk Stratification of Hematuria Patients for Urothelial Carcinoma. Diagnostics. 2025; 15(14):1739. https://doi.org/10.3390/diagnostics15141739
* When lower 0.15 cut point on test report is used
** When higher 0.54 cut point on test report is used

THE CXBLADDER SUITE: MONITOR AND SURVEILLANCE PLUS
ALTERNATIVE TO CYSTOSCOPY FOR NMIBC
1
PATIENTS UNDERGOING SURVEILLANCE FOR RECURRENCE

NMIBC
1
CANCER SURVEILLANCE RECURRENCE
NEGATIVE RESULT
RULE OUT BLADDER CANCER RECURRENCE
The test combines a High Negative Predictive Value
with High Sensitivity (it picks up most cancers)

•In development, showing improved
performance
PERFORMANCE
•Sensitivity: 93%
2,3
•Specificity: N/A
•Negative Predictive Value: 97%
2,3
•Positive Predictive Value: N/A
•Sensitivity: not yet published
•Specificity: not yet published
•Negative Predicative Value: not yet
published
•Positive Predictive Value: not yet
published
WHEN IT IS USED:
At any surveillance time point 9 months
after the most recent cancer diagnosis
At any surveillance time point after the
first surveillance cystoscopy (6 weeks)
COMMERCIALLY AVAILABLE
Globally available•USA: CPT-PLA code targeted for Jun
2027, reimbursement from Jan 2028
•APAC: Soft launch from Q2 FY28
GUIDELINES
NCCN
4
2bNot yet available for assessment
MEDICARE
US$760 (non-covered)Seeking US$1,800
5
(not yet covered)
9
1.NMIBC: non-muscle invasive bladder cancer
2.Kavalieris et al. (2017) Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. J Urol 2017;197:6,1419-1426.
3.Lotan et al. (2017) Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations. Elsevier; 2017; 1–8.
4.NCCN: National Comprehensive Cancer Network
5.Seeking pricing by way of crosswalk

•Cxbladder avoids invasive, unnecessary procedures saving >US$500/patient
2
•Only 63% of counties in the US have a registered urologist
3

•Only 13% of high-risk microhematuria patients receiving a cystoscopy
4

•The number urologists per person over 65 is falling
5
potentially delaying diagnosis
•Medicare reimbursement is declining
6
1.AUA Guidelines cite incidence of bladder cancer in microhematuria risk categories from 0.4-6%. 5% is an example
2.Tyson et al (2024) Budgetary Impact of Including the Urinary Genomic Marker Cxbladder Detect in the Evaluation of Microhematuria Patients - PubMed (PMID: 37914255)
3.https://www.auanet.org/research-and-data/aua-census/census-results
4.https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.25048
5.Nam et al. (2021) Projected US Urology Workforce per Capita, 2020-2060 JAMA Network Open Published Online:November16,2021
6.https://www.cms.gov/medicare/physician-fee-schedule/search
DRIVING ECONOMIC VALUE FOR PATIENTS, HOSPITALS AND PAYERS
CXBLADDER DELIVERS CLINICAL UTILITY, PATIENT SATISFACTION, IMPROVED ACCESS AND ECONOMIC VALUE
Illustration shows incidence of bladder cancer in microhematuria
populations at 5%
1
With Triage Plus, 85% of patients can avoid cystoscopy, 15% receive
cystoscopy to find the same 5 cancer patients
10
CANCER INCIDENCE IN MICROHEMATURIA PATIENTSCYSTOSCOPIES SAFELY AVOIDED USING CXBLADDER
Cystoscopy
No cancer
Cystoscopy
Cancer
No cystoscopy
No cancer
Cystoscopy
Cancer
Cystoscopy
No cancer

US$10.6b
Global TAM
1
CXBLADDER MARKET OPPORTUNITY
CXBLADDER OFFERS A SIGNIFICANT ADDRESSABLE GLOBAL MARKET ANNUALLY
~17m0.47m | 2.71m | 3.46m1.7m ~58k ~300k US$2.0b830m
~12m0.34m | 1.96m | 2.5m1.7m ~180k ~1mUS$1.9b600m
APAC
Primary growth
focus due to higher
CMS pricing
NZ market mature.
Australia and SEA in
business development
New market accessed
via IVD / kitted tests
1.Pacific Edge estimate combining US, APAC and Europe. See slides 36-38 for details.
2.RDM: Residual Disease Monitoring
3.TRM: Therapeutic Response Monitoring
4.Management estimates derived from referred hematuria data in Woldu et al (2021), so do not add to ~7m figure for total incidence. See slides 36-38 for details.
All
hematuria
Microhematuria
4
Low | Intermediate | High
Gross
4

Hematuria
Annual cases of
bladder cancer
Living with bladder cancerTAMPopulation
SURVEILLANCE
(RDM
2
, TRM
3
, RECURRENCE)
PATIENT/DISEASE MANAGEMENT
(CLINICAL DECISION MAKING)
11
~7m0.20m | 1.14m | 1.46m0.7m ~90k ~750k US$6.7b340m

12
PACIFIC EDGE CATALYSTS FOR LONG-TERM SUSTAINABLE GROWTH
1
AN EXPANDING SERVICEABLE MARKET AND REVENUE
1
Medicare coverage
high-risk Microhematuria
2
Surveillance Plus
launched
3
Medicare coverage
Gross Hematuria patients
4
Kitted RUO
2
launch
5
Kitted IVD
3
launch
6
New product
launch
N E A R-T E R MM E D I U M-T E R ML O N G E R-T E R M
1.Illustrative only. The curves indicate the sequence and relative scale of expected market expansion, not forecast revenue
2.RUO is for “research use only” and limits the clinical claims that can be made and the payment options
3.IVD is an in vitro diagnostic and subject to country-specific product registrations, regulations and reimbursement processes
4.Profitability threshold determined on an annualizedbasis across all products with a blended ASP >$NZD 1,450
PE GROUP profitability at
~55,000 tests/year
4
C U M U L A T I V E R E V E N U E

STRATEGY AND PROGRESS
13

VALUE CREATION THROUGH THREE PILLARS
OUR PEOPLE
OUR PROCESSES
OUR IP, KNOWLEDGE
AND EXPERIENCE
OUR CLINICAL STUDIES
PARTNER SITES
OUR INVESTORS
EARLY DETECTION AND
CLINICALLY ACTIONABLE CARE
INNOVATION PIPELINE FOR
CLINICAL APPLICATIONS
INCLUSIVE WORKPLACE
DRIVEN BY OUTCOMES
INCREASED LONG-TERM
SHAREHOLDER VALUE
EXCELLENT PATIENT EXPERIENCE
AND ACCURATE RESULTS
INPUTSOUTPUTS
A VALUES DRIVEN, DIVERSE, RESULTS-FOCUSED CULTURE
SCALABLE PROCESSES, TRAINING & QUALITY SYSTEMS,CONTINUOUS IMPROVEMENT
DIGITALIZED ARCHITECTURE, AUTOMATED OPERATIONS, REAL-TIME ANALYSIS
14

15
TRIAGE AND TRIAGE PLUS – THE ONLY TESTS COVERED UNDER THE DRAFT LCD
MEDICARE COVERS ~71M PEOPLE - THE LARGEST SINGLE REIMBURSEMENT DECISION GLOBALLY
July 2026
LCD ‘Notice and
Comment’ period
closes
May 2026
Novitas publishes DL40378
June
2026
Sept
2026
Estimated time for the LCD to
become final and effective
(Pacific Edge estimate)
1.UBB is urine-based biomarker
“Use of validated multi-analyte UBBs may be reasonable and necessary to support
risk-stratification in appropriately counseled, intermediate-risk patients with MH
who are considering deferral of cystoscopy.”
DRAFT LCD: ‘Urine-based Biomarkers in Patients with Microhematuria’ (DL40378)
Feb 2026
Novitas’ CAC Panel
expresses clear
support for UBBs in
hematuria evaluation
Feb 2025
Triage included in
AUA Microhematuria
Guideline
Dec
2026
Mar
2026
Jan
2026
Jan 2026
Kaiser RWE published
supporting Triage.
Largest ever UBB
1

hematuria study
2025

16
EXPANDING COVERED INDICATIONS WITH OUR CLINICAL EVIDENCE PROGRAM
VALIDATION STUDIES SEEKING TO REDEFINE AUA RISK THRESHOLDS
Expected window for updated literature review
of microhematuria by AUA guideline committee
Dec
2026
STRATA 2
Jun
2027
Sept
2027
Dec
2027
Mar
2027
AUSSIE
microDRIVE
Pooled Analysis MH
Pooled Analysis GH
(DRIVE AUSSIE, microDRIVE)
Key Supporting Studies
STRATA second publication
- CU of Triage
AUSSIE Clinical Validation
- CVof Triage Plus
microDRIVE Clinical Validation
- CV of Triage Plus
Pooled Analysis MH Clinical Validation
2
- CV of Triage Plus
Pooled Analysis GH Clinical Validation
2
- CV of Triage Plus

US COMMERCIAL PAYERS: MEDICARE COVERAGE EXPECTED TO UNLOCK VOLUMES
LEVERAGING COVERAGE TO DIVERSIFY CUSTOMER BASE TO PRIVATE INSURERS
1.https://www.census.gov/library/publications/2025/demo/p60-288.html
2.https://data.cms.gov/summary-statistics-on-beneficiary-enrollment/medicare-and-medicaid-reports/medicare-monthly-enrollment
3.https://content.naic.org/sites/default/files/2024-annual-health-industry-commentary.pdf
~1,200
US private health
insurance payers
3
71m
Medicare
insured lives
2

223m
US private
insured lives
1

17
PACIFIC EDGE PAYER MIX (2H 26)
60%
20%
16%
2%
2%
COMMERCIAL
MEDICARE
MEDICARE
ADVANTAGE
VETERANS AFFAIRS
MEDICAID AND
MANAGED MEDICAID

US COMMERCIAL STRATEGY WITH DRAFT MEDICARE COVERAGE
INTEGRATED DELIVERY NETWORKS ARE THE TOP TARGET FOR INTERMEDIATE RISK MICROHEMATURIA
18
1.Management estimates derived from referred hematuria data in Woldu et al (2021). See slides 36-38 for details.
2.Share of patient volume figures are management estimates
51%
30%
8%
7%
4%
Hospital Networks
Academic Centers
Veterans
Administration
Kaiser Permanente
Other
684k
60%
40%
IDNsPrivate Practice
HEALTHCARE PROVIDER TYPE
(SHARE OF PATIENT VOLUME)
2
INTEGRATED DELIVERY NETWORKS
(SHARE OF PATIENT VOLUME)
2
PRIVATE PRACTICE
(SHARE OF PATIENT VOLUME)
3
1.14m
1
80%
20%
Large Urology
Group Practices
Community
Urology
456k
Low risk
80%20%
Intermediate risk
75%25%
High risk
34%66%
FemaleMale
AUA RISK CATEGORY BY SEX (AT BIRTH)
(PERCENTAGE OF PATIENTS)
1

COMMERCIAL TESTS STABILIZED; SET TO RISE WITH FINAL COVERAGE
19
US TOTAL TEST VOLUME
1
AND COMMERCIAL PRODUCT MIX
1.Total Laboratory Throughput including commercial, pre-commercial and clinical studies testing
COMMERCIAL AND TOTAL THROUGHPUT STABILIZED
•Commercial and total throughput stable over last
three quarters
•Sales efficiency improved as sales FTE lowered to
address cash burn
•Seeking to shift commercial product mix towards
Triage Plus (US$1,328) on every eligible patient
3,786
3,010
3,375
3,295
1,187
1,015
689
540
4,973
4,025
4,064
3,835
-
1,000
2,000
3,000
4,000
5,000
6,000
Q2 26Q3 26Q4 26Q1 27
TEST VOLUME
Clinical and non-commercial tests Commercial Volume
85%
85%
87%
86%
1%
2%
1%
1%
14%
13%
13%
13%
0%
20%
40%
60%
80%
100%
Q2 26Q3 26Q4 26Q1 27
PRODUCT MIX (%)
TriageDetectTriage PlusMonitor

APAC CHARTING A PATH TO PROFITABILITY
20
1.Total Laboratory Throughput in Asia and Pacific including commercial, pre-commercial and clinical studies testing
2.APAC Commercial and Clinical Operations cash burn figure is calculated on a direct cost basis and excludes R&D costs
APAC TOTAL TEST VOLUME
1
AND COMMERCIAL PRODUCT MIX
TRIAGE PLUS DRIVING IMPROVED UNIT ECONOMICS
•Commercial testing volumes growing for four
consecutive quarters
•Triage Plus volumes growing; potential for ~20%
more revenue per test
•APAC contributed 19% of operating revenue in 2H 26
with $2.0m in FY26; cash burn rate
2
of $0.17m in Q1
FY27
•Repricing in 2025 created on average 25% more
revenue per test
971
1,001
1,026
1,158
339
409
492
123
1,310
1,410
1,518
1,281
-
200
400
600
800
1,000
1,200
1,400
1,600
Q2 26Q3 26Q4 26Q1 27
TEST VOLUME
Clinical and non-commercial tests Commercial Volume
45%
44%
41%
37.8%
43%
43%
46%
41.8%
0%
2%
1%
7.6%
12%
11%
12%
12.8%
0%
20%
40%
60%
80%
100%
Q2 26Q3 26Q4 26Q1 27
PRODUCT MIX (%)
TriageDetectTriage PlusMonitor

21
NEXT GENERATION PRODUCTS ALREADY DELIVERING STRATEGIC VALUE
TRIAGE PLUS AND SURVEILLANCE PLUS OFFER SUPERIOR PERFORMANCE, PRICING AND MARGIN
ADVANCING IVD DEVELOPMENT FOR INTERNATIONAL MARKETS
•Triage Plus and Surveillance Plus will be offered as CAP/CLIA-
approved LDTs
1
providing service to the entire USA
•International markets require a different approach in which Pacific
Edge seeks to create a ‘kitted’ IVD medical device
•Pacific Edge is simplifying its tests to create Triage Plus IVD for
decentralized lab deployment and international market expansion.
•Key objectives:
•Establishing IVD regulatory framework for our next
generation tests that includes IVD-R (Europe), FDA (USA) and
ISO-13485
2
(International)
•Prototype development plans are in place and ready to be
implemented subject to budget approval
1.CAP is the College of American Pathologists, CLIA is the Clinical Laboratory Improvement Amendments and LDT is a laboratory developed test
2.IVD-R is a European In Vitro Diagnostic Regulation; FDA, US Food and Drug Administration; ISO International Organization for Standardization

FY 26 FINANCIAL PERFORMANCE: POSITIONING FOR MEDICARE RE-COVERAGE
COST SAVINGS MINIMIZE CASH BURN; $36.1 MILLION CAPITAL RAISE IN MAY 2026 STRENGTHENS BALANCE SHEET
1.Net cash, cash equivalents and short-term deposits at the end of the period
22
Financial Period (NZ$M)
1H 26
(Unaudited)
2H 26
(Unaudited)
FY 26
(Audited)
FY 25
(Audited)
2H 26 vs 1H
26
FY 26 vs FY 25
Operating Revenue$5.9$5.6$11.5$21.8(6.4%)(47.4%)
Total Revenue$7.1$6.5$13.6$24.6(9.3%)(44.8%)
Operating Expenses$26.2$23.1$49.4$54.6(11.9%)(9.5%)
Net Loss After Tax($19.1)($16.7)($35.8)($30.0)(12.8%)19.5%
Cash Receipts from Customers$8.0$5.2$13.2$21.6(34.3%)(38.7%)
Net Cash Flows to Operating Activities($19.0)($12.9)($31.9)($24.7)(32.1%)29.1%
Net Cash
1
$22.1$7.8$7.8$22.6(64.8%)(65.5%)
Monthly Cash Burn $3.3$2.4$2.9$2.3(27.7%)23.4%

OUTLOOK
POSITIONED TO UNLOCK VALUE THROUGH UPCOMING COMMERCIAL, CLINICAL AND INNOVATION MILESTONES
LONG-TERM VALUE CREATION
RESEARCH INNOVATION
MEDIUM-TERM VALUE CREATION
CLINICAL EVIDENCE GENERATION
NEAR-TERM VALUE CREATION
COMMERCIAL CATALYSTS
•Case-by-case reimbursement expected
for Triage and Triage Plus under draft LCD
•Final LCD published by end of 2026
•US customers adopt Triage Plus at
US$1,328/test
•Building US Commercial payer medical
policy momentum
•Evidence generation program delivers
sustained strategic value
•US commercial payer policy for Triage
and Triage Plus drives test adoption
•AUA guideline review (2027/28)
expected to expand serviceable market
•Investigator initiated trials (IITs) generate
novel evidence for new indications
•Triage Plus and Surveillance Plus deliver
better patient outcomes at higher
margin pricing for improved unit
economics
•SurveillancePlus CPT-PLA coding
submission in June 2027 and claim-by-
claim revenue after 1 Jan 2028
•US$1,800 CMS pricing for Surveillance
Plus in FY28
•Product simplification and kitted IVD
products enable de-centralized
deployment in international markets
23

APPENDIX
24

PACIFIC EDGE IS FOUNDED ON DELIVERING POSITIVE OUTCOMES FOR SOCIETY
WE CREATE VALUE BY PRIORITISING OUR PATIENTS, OUR PHYSICIANS AND OUR PEOPLE
WE PUT PATIENTS FIRST IN EVERYTHING WE DO
•WE are committed to customer success
•WE are guided by data and evidence
•WE are trusting and transparent
•WE support our teammates
•WE celebrate successes, large and small
25
Our Mission
To help improve people’s lives and patient
outcomes by providing leading solutions for the
early detection and management of cancer
Our Vision
A world where the early diagnosis and better
treatment of cancer is within reach of everyone

PACIFIC EDGE – THE FIRST MOVER AND LEADER IN BLADDER CANCER DIAGNOSTICS
A GLOBAL COMPANY WITH A GLOBAL OPPORTUNITY
26
1.See slides44-46 for assumptions
US$10.6b
1
Global Market Opportunity

Jan 2026
Kaiser RWE published
supporting Triage.
Largest ever UBB
1

hematuria study
Feb 2026
CAC Panel expresses
clear support for
UBBs in hematuria
evaluation
May 2026
Novitas publishes
DL40378 with
coverage for Triage
Plus and Triage
Dec 2014
Launch of
Cxbladder
Triage
Nov 2023
Kaiser EMR
integration
goes live
Dec 2022
Lotan et al:
Enhanced
Cxbladder
Tests Deliver
Improved
Performance.
Journal of
Urology
Feb 2018
Cxb Triage
adopted into
Canterbury
Community Health
Pathways with
primary care
referral
2011
2011
Pacific Edge
Diagnostics
New Zealand
(PEDNZ)
established
2012
Dec 2012
Launch of Pacific Edge
Diagnostics USAand
Cxb Detect
2013
Mar 2013
First commercial
sale (Cxb Detect)
for PEDUSA
May 2013
First commercial
sale (Cxb Detect)
for PEDNZ
2014
2015
Dec 2015
Launch of
Cxbladder
Monitor
2016
2018
2019
2020
Jun 2020
Kaiser Permanente,
approves commercial
use of Cxbladder
Jul 2020
Medicare
reimbursement of
Cxbladderat
US$760/test
2021
Aug 2021
Cxbladder reaches
70% public
healthcare
coverage in NZ
2022
2023
2024
May 2024
STRATA podium
presentation at
AUA 2024.
Study published
in Journal of
Urology
TIMELINE: COMPANY MILESTONES
2025
Feb 2025
Triage included in AUA
Microhematuria
Guideline
Apr 2025
Medicare non-
coverage
effective
Nov 2025
Triage Plus gets CMS
draft price of
US$1,328
2026
1.UBBs are urine-based biomarkers – a term adopted by AUA in their guidelines

FINANCIAL PERFORMANCE OPERATING EXPENSES
ALL COSTS REDUCED WITH LARGEST REDUCTION IN SALES AND MARKETING

28
Financial Period (NZ$M)
1H 26
(Unaudited)
2H 26
(Unaudited)
FY 26
(Audited)
FY 25
(Audited)
2H 26 vs
1H 26
FY 26 vs
FY 25
Laboratory Operations $5.9$5.7$11.6$12.5(2.8%)(7.1%)
Research $7.1$6.4$13.4$14.6(9.9%)(8.2%)
Sales and Marketing $8.5$6.8$15.2$17.5(20.0%)(13.2%)
General Administration$4.8$4.3$9.1$9.9(11.8%)(8.1%)
Total operating expenses $26.2$23.1$49.4$54.6(11.9%)(9.5%)

PACIFIC EDGE’S EVIDENCE PROGRAM SEEKS TO CHANGE CLINICAL PRACTICE
Clinical Evidence
AV, CV, CU
HEALTHCARE PAYERS
(Medicare, Kaiser
Permanente, Veterans
Administration, private
payers, etc).
- Change Medical Policy
(practice)
- Change Reimbursement
Policy
PROFESSIONAL SOCIETIES
(AUA, EAU, NCCN)
- Change Standard of Care
Guidelines
Guidelines change:
- Healthcare Payer Medical
and Reimbursement
Policies
Guidelines change:
- Clinical Practice
UROLOGISTS - Change Clinical Practice
EVIDENCE DEVELOPED IN A STRUCTURED FRAMEWORK:
•Analytical Validity (AV): Evidence that a test is repeatable in the lab for a given indication and population
•Clinical Validity (CV): Evidence a test works in the same way on an independent eligible population for a given indication
•Clinical Utility (CU): Evidence that a test changes clinical practice in the hands of a physician; CU evidence obtained through randomized control trials is
required to change standard of care guidelines (in addition to AV and CV evidence)
•Real World Evidence (RWE): CU verification of the real-world use of the test in clinical practice, usually through regular use of the test by physicians
AUDIENCE
EVIDENCE USE
29

Calendar year
Pre
2023
202320242025202620272028
Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2
STRATA
DRIVE
AUSSIE
microDRIVE
Pooled CV
CREDIBLE
HEMATURIA EVALUATION FIVE-YEAR CLINICAL STUDIES ROADMAP
*
*
*
*
*
Publication Submitted
Records review / follow-up
Database lock
Legend:
Pre-activation (docs, CTA etc)
SIV
Enrollment
Data Cleaning
*
DBL
DBL
DBL
30

Calendar year
Pre
2023
202320242025202620272028
Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2
“The 1800”
1
LOBSTER
OCTOPUS
*
SURVEILLANCE FIVE-YEAR CLINICAL STUDIES ROADMAP
31
Publication Submitted
Records review / follow-up
Database lock
Legend:
Business case approved
SIV
Enrollment
Data Cleaning
*
DBL
Scheduled surveillance visits
CAB
2
1.“The 1800” is the Surveillance Plus development dataset
2.CAB is the Pacific Edge Clinical Advisory Board. It was convened at SUO in Arizona to review and confirm the clinical study trial design for OCTOPUS

32
DRIVING CLINICAL VALUE FOR PHYSICIANS, HOSPITALS AND PAYERS
COMPELLING CLINICAL EVIDENCE CHANGES CLINICAL PRACTICE, MEDICAL POLICY AND GUIDELINES
1.Clinical Utility (CU) - Evidence a test that can usefully change patient management within the context of care for the defined population and indication Clinical Validity (CV) - Evidence a test
works in the same way on an independent eligible population for a given indication. Analytical validity (AV) - Evidence a test is repeatable in the lab for a given indication and population
STUDY
TEST AND EVIDENCE
PUBLICATION DATE
(1)
1. STRATA Clinical Utility
- CU of Triage
Published May 2024
2. Automated RNA & DNA extraction
- AV of Triage, Detect and Monitor
Published September 2024
3. Triage Plus Analytical Validation
- AV of Triage Plus
Published July 2025
4. DRIVE Clinical Validation
- CV of Triage Plus
Published October 2025
5. STRATA second publication
- CU of Triage
Q3 2027
6. AUSSIE Clinical Validation
- CVof Triage Plus
Q3 2026 (+1Q)
7. microDRIVE Clinical Validation
- CV of Triage Plus
Q1 2027 (+1Q)
8. Surveillance Plus Analytical Validation
- AV of Surveillance Plus
Q2 2027 (+3Q)
9. Pooled Analysis MH Clinical Validation
2
- CV of Triage Plus
Q2 2027 (+1Q)
10. Pooled Analysis GH Clinical Validation
2
- CV of Triage Plus
Q2 2027 (+1Q)
11. LOBSTER Clinical Validation
- CV of Monitor/Surveillance Plus
Q3 2027 (+3Q)
12. CREDIBLE Clinical Utility
- CU of Triage Plus
Q1 2028 (at risk)
13. OCTOPUS Clinical Utility
- CU Surveillance Plus
No timeline at this point
1
All dates are calendar year and our best current estimates
2
The MH and GH pooled analysis brings together data from DRIVE, AUSSIE and microDRIVE
Already published evidence
Expected to be published before AUA microhematuria guideline committee initiates next literature review in Q3 2027

INDEPENDENT STUDIES SUPPLEMENT OUR EVIDENCE PORTFOLIO
HIGH IMPACT RESEARCH AT LOW COST
1.All dates are calendar year and our best current estimates
2.Filson et al (2026); Real-World Utility of Cxbladder Triage for Patients with Microhematuria: A Matched Cohort Study, Urology Practice® (2026), doi:
10.1097/UPJ.0000000000000972.
3.BCG: Bacillus Calmette–Guérin is a bacterium instilled into the bladder that triggers an immune response that targets and destroys cancer cells.
4.MIBC: Muscle Invasive Bladder Cancer
INDEPENDENT STUDY FOCUSINSTITUTIONTEST AND EVIDENCE TYPE
PUBLICATION
DATE
1
Real World Utility of Triage in MH: A Matched
Cohort Study
Kaiser Permanente, USCU Triage (RWE)Q1 2026
2
Patient preference and satisfaction of
“biomarkers vs cystoscopy”
Mayo Clinic, USCU MonitorQ3 2026
NZ Hematuria Pathway comparing T/D with
Triage Plus on AUSSIE samples
Canterbury DHBCU of Triage PlusQ3 2026
Retrospective concordance of Triage and Triage
Plus in the Kaiser System
Kaiser Permanente, USCU Triage Plus2027
Test utility in screening patients at risk for
bladder cancer
UT Southwestern, USCU Triage Plus 2027
Test utility in assessing therapy success in a
reduced chemotherapy protocol for upper tract
tumors
Israel Institute of
Technology, Israel
CU Monitor
CU Surveillance Plus
2027
Test utility in assessing response to BCG
3
in high-
grade bladder cancer patients
University of Miami, US
CU Monitor
CU Surveillance Plus
2027
Test utility for the surveillance of MIBC
4
treated
with bladder sparing methods (PRESERVE Trial)
Cleveland Clinic, US
CU Monitor
CU Surveillance Plus
2028
A Randomized Trial of Apalutamide in Non-
Muscle Invasive Bladder Cancer
National Institutes of
Health, US
CU Monitor
CU Surveillance Plus
2029
Already published evidence
33
•Investigator initiated trials (IITs) are
independent studies in which Pacific Edge
typically provides free testing, so provide
significant value at low cost
•IITs extend the evidence portfolio for new
indications of existing tests and may inform
new ‘core’ clinical trials
•IITs are an important part of Key Opinion
Leader (KOL) engagement and generate
publications or podium presentations that
give profile to Cxbladder and Pacific Edge

BACKGROUND ON NMIBC AND MIBC
•Bladder Cancer
•An estimated 83,190 patients were diagnosed with bladder cancer in the USA in 2024 at an average age of 73
1
•Non-muscle invasive Bladder Cancer (NMIBC)
•NMIBC tumors represent approximately 75% of the bladder cancer diagnoses each year (CIS, Ta and T1)
•NMIBC tumors are localized and present on the lining of the bladder wall and shed cancer cells and cell-free DNA/RNA into the urine in the bladder
•NMIBC tumors are highly treatable with surgery/resection and deemed cancer free after surgery/resection
•NMIBC patients are placed on a surveillance protocol after surgery/resection, because recurrence can be 50-70% within the first two years
2
•NMIBC → TURBT → Surveillance
•Muscle-invasive Bladder Cancer (MIBC)
•MIBC tumors represent approximately 25% of the bladder cancer diagnoses each year (T2-4)
•MIBC tumors differ from NMIBC tumors, because they shed cells/nucleotides to the blood
•MIBC patients have advanced/serious disease, require high-levels of intervention (radical cystectomy followed by multiple therapies)
•MIBC patients are not deemed cancer free after cystectomy and frequently monitored for residual and metastatic disease
•MIBC → Cystectomy → Monitoring
1.American Cancer Society. Cancer Facts & Figures 2024
2.Holzbeierlein J, Bixler BR, Buckley DI, et al. Diagnosis and treatment of
non-muscle invasive bladder cancer: AUA/SUO guideline: 2024
amendment. J Urol. 2024;10.1097/JU.0000000000003846.

NMIBC STANDARD OF CARE: INTERVENTION AND SURVEILLANCE
•NMIBC Standard of Care – Intervention
•After NMIBC diagnosis, the standard intervention is a Trans-Urethral Resection of a Bladder Tumor (TURBT)
•TURBT involves inserting a camera into the urethra and the use of small instruments like a wire loop or laser to cut or burn away the tumor tissue
•Patients are deemed cancer free post TURBTwhen muscles and tumor margins are confirmed free of disease by pathology
•A resection biopsy taken during surgery is used to stage the tumor (T0, Ta, CIS, T1-4) and determine the grade (low or high grade) which also
provides the risk of recurrence.
•All NMIBC patients are then classified into risk categories based on this information (low, intermediate and high risk).
•NMIBC Standard of Care - Surveillance
•BCG (bacillus calmette guérin) is administered for several weeks after TURBT to initiate an immune response towards the tumor. Some
patients are ‘non-responders’
•A cystoscopy at 3 months is recommended for every patient
•Following the 3-month cystoscopy, patients are recommended for routine surveillance protocols involving cystoscopy and imaging among
others based on their risk category
•Due to the high burden of these protocols, the average patient only stays on surveillance for1.8 years not 5
1
as recommended by most
guidelines
1.AUA AQUA Registry

SOURCES AND ASSUMPTIONS - TOTAL ADDRESSABLE MARKET (US)
36
REGIONSTATISTICSOURCE
UNITED STATES
Population 341,762,685https://www.census.gov/popclock/
Incidence of hematuria7,000,000
Presentation from Dr Sia Daneshmand (Director of
Urologic Oncology and Clinical Research, USC) July 2019
Referred for clinical workup3,500,000
Presentation from Dr Sia Daneshmand (Director of
Urologic Oncology and Clinical Research, USC) July 2019
Proportion of gross hematuria amongst
those referred for clinical workup700,000Pacific Edge estimate
Proportion of microhematuria amongst
those referred for clinical workup2,800,000Pacific Edge estimate
Proportion of low-risk microhematuria 200,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
Pacific Edge estimates to account for AUA 2025
guidelines
Proportion of intermediate-risk
microhematuria 1,140,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
Pacific Edge estimates to account for AUA 2025
guidelines
Proportion of high-risk microhematuria 1,460,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
Pacific Edge estimates to account for AUA 2025
guidelines
Annual cases of bladder cancer 84,870
National Cancer Institute
Patients living with bladder cancer 744,044
National Cancer Institute
Test opportunities 4,616,066Pacific Edge estimate
Price of Cxbladder (US$)
$1,328 for Cxbladder Triage Plus, $1,800 for Cxbladder
Surveillance Plus
TAM (US$billion)$6.7

SOURCES AND ASSUMPTIONS - TOTAL ADDRESSABLE MARKET (EUROPE)
37
REGIONSTATISTICSOURCE
EUROPE (EXCLUDING
RUSSIA)
Population
600,000,000World-population - Europe
World-population - Russia
Incidence of hematuria12,000,000
Science Direct
Referred for clinical workup6,000,000
Presentation from Dr Sia Daneshmand (Director of
Urologic Oncology and Clinical Research, USC) July 2019
Proportion of gross hematuria amongst
those referred for clinical workup1,200,000Pacific Edge estimate
Proportion of microhematuria amongst
those referred for clinical workup4,800,000Pacific Edge estimate
Proportion of low-risk microhematuria 340,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
Pacific Edge estimates to account for AUA 2025
guidelines
Proportion of intermediate-risk
microhematuria 1,960,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
Pacific Edge estimates to account for AUA 2025
guidelines
Proportion of high-risk microhematuria 2,500,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
Pacific Edge estimates to account for AUA 2025
guidelines
Annual cases of bladder cancer 180,000
Uroweb
Patients living with bladder cancer 900,000Pacific Edge estimate - 5 years of annual cases
Test opportunities 7,350,000Pacific Edge estimate
Price of Cxbladder EURO€245Pacific Edge estimate
TAM (US$billion)$2.0

SOURCES AND ASSUMPTIONS - TOTAL ADDRESSABLE MARKET (APAC)
38
REGIONSTATISTICSOURCE
APAC (EXCLUDING INDIA
AND CHINA)
Population
830,000,000
World population - Southeast Asia
Population Pyramid - Japan
Population Pyramid - Hong Kong
Incidence of hematuria16,600,000
Science Direct
Referred for clinical workup
8,300,000
Presentation from Dr Sia Daneshmand (Director of
Urologic Oncology and Clinical Research, USC) July 2019
Proportion of gross hematuria amongst
those referred for clinical workup
1,660,000
Pacific Edge estimate
Proportion of microhematuria amongst
those referred for clinical workup
6,640,000
Pacific Edge estimate
Proportion of low-risk microhematuria
470,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
AUA 2025 guidelines
Proportion of intermediate-risk
microhematuria
2,710,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
AUA 2025 guidelines
Proportion of high-risk microhematuria
3,460,000
Woldu, S, et al. Evaluation of the New American Urological
Association Guidelines Risk Classification for Hematuria;
AUA 2025 guidelines
Annual cases of bladder cancer
58,000
WHO
Hong Kong
Patients living with bladder cancer 290,000Pacific Edge estimate - 5 years of annual cases
Test opportunities 3,494,000Pacific Edge estimate
Price of Cxbladder (US$)$550Pacific Edge estimate
TAM (US$billion)$1.9

KEY CLINICAL ADVISORS AND CONSULTANTS
Associate Professor Katie Murray, DOMS, FACS
Institution: NYU Langone
Relationship: Consultant, CAB member,
Brief Bio: Published >80 articles. Deputy Editor for J Urol.
Leadership roles for SUO Young Urologic Oncology Clinical Trials
Professor Jonathan Wright, MD, MS, FACS
Institution: Fred Hutchinson Cancer Center at UW
Relationship: Consultant, CAB member, CT PI
Brief Bio: Member of ACS, SUO, AUA
Professor Wade Sexton, MD
Institution: University of South Florida & Moffitt Cancer Center
Relationship: Consultant, CAB member
Brief Bio: Published >100 articles. NCCN Bladder Cancer
Guidelines, AUA Annual Board Review Course
Professor Jay Raman, MD
Institution: Penn State and Hershey Medical Center
Relationship: Consultant, CAB member, CT PI
Brief Bio: Published >350 articles. Chair of AUA Office of Education
and Past-President of the Mid-Atlantic AUA section. Urology
Advisory Council for ACS, Hematuria Guidelines member
Associate Professor Kristen Scarpato, MD, MPH, FACS
Institution: Vanderbilt University Medical Center
Relationship: Consultant, CAB member, CT PI
Brief Bio: SUO Education Committee, AUA Core Curriculum,
Urology Practice Editorial Committee
Professor Yair Lotan, MD
Institution: UT Southwestern Medical Center
Relationship: Consultant, CAB member, IIT PI, CT PI
Brief Bio: Published >500 articles. Contributor to AUA/ASCO/ASTRO
MIBC and Hematuria Guidelines. Chair of AUA Core Curriculum. BCAN
Adboard
Professor Sam Chang, MD, MBA
Institution: Vanderbilt Cancer Center
Relationship: Consultant, CAB member
Brief Bio: Published >200 articles. Chair of AUA NMIBC Guidelines,
SUO Executive Board, ABU/AUA Examination Committee, BCAN
Adboard, AUA representative to the AJCC
Assistant Professor John Sfakianos
Institution: Icahn School of Medicine at Mount Sinai
Relationship: Consultant, CAB member
Brief Bio: Published >20 articles. Reviewer for J Urol and Urologic
Oncology
Professor Dan Barocas, MD, MPH, FACS
Institution: Vanderbilt University Medical Center
Relationship: Consultant, CAB member
Brief Bio: Published >100 articles. AUA Guidelines panel for
microscopic hematuria. Reviewer for AUA educational materials
Associate Professor, Siamak Daneshmand, MD
Institution: Keck School of Medicine at USC
Relationship: Consultant, CAB member, CT PI
Brief Bio: Published >200 articles. Editorial board of the J Urol,
Bladder Cancer Journal, Current Opinions in Urology, BCAN Adboard,
AUA/SUO Guideline Committee on NMIBC
ASCO: American Society of Clinical Oncology
ASTRO: American Society of Radiation Oncology
AUA: American Urological Association
BCAN: Bladder Cancer Advocacy Network
CAB: Clinical Advisory Board
CT PI: Clinical Trials Principal Investigator
FACS: Fellow of the American College of Surgeons
IIT PI: Investigator Initiated Trial Principal Investigator
J Urol: Journal of Urology
KOL: Key Opinion Leader
MPH: Master of Public Health
SUO: Society of Urologic Oncology
39

INDEPENDENT DIRECTORS
SARAH PARK
ANATOLE MASFEN
BRYAN WILLIAMS
ANNA STOVE
TONY BARCLAY
SIMON FLOOD
Chairman
Simon has spent more than 25
years in the global investment
management industry having held
senior Investment and Business
Leadership roles in some of the
world’s pre-eminent investment
management firms including
Merrill Lynch Investment Managers
Lion Global Investors and AXA
Investment Managers
DR PETER MEINTJES
Chief Executive Officer
Peter is a molecular diagnostics and
genomics leader focused on
nascent market development of
disruptive innovations to drive
commercial success. Prior to joining
Pacific Edge, he was based in
Boston in a succession of diagnostic
leadership roles. Most recently he
was the Chief Commercial Officer
at Eurofins Transplant Genomics
and before that he was CEO at
Omixon
SENIOR LEADERSHIP TEAM
GRANT GIBSON DR TAMER ABOUSHWAREB DR JUSTIN HARVEY
Chief Financial Officer Chief Medical Officer Chief Technology Officer
GLEN COSTIN DARRELL MORGAN ZOE O’DONNELL
President Asia Pacific Chief Operating Officer Global Head of People & Culture
PROFESSOR PARRY GUILFORD WILLY IGLESIAS
Chief Scientific Officer Chief Digital Officer
PACIFIC EDGE BOARD AND MANAGEMENT
40

FOR MORE INFORMATION:
Dr. Peter Meintjes
Chief Executive Officer
email: peter.meintjes@pelnz.com
Grant Gibson
Chief Financial Officer
email: grant.gibson@pelnz.com
Pacific Edge
87 St David Street, PO Box 56, Dunedin, New Zealand
P +64 3 577 6733 Within NZ 0800 555 563
email: investors@pacificedge.co.nz
www.pacificedgedx.com
41